Cambodia Planning Three More Major Infrastructure Projects

Cambodia is planning three more major infrastructure construction projects, pointed out this morning Prime Minister Samdech Akka Moha Sena Padei Techo Hun Sen.
At the inauguration ceremony of National Road (NR) No. 11 and Prey Veng road with the total length 96.48 kilometres from Neak Loeung, Junction with NR No. 1, Prey Veng province to Thnal Totoeung, Junction with NR No. 7 Thbong Khmum province, Samdech Techo Hun Sen said the three construction projects include a bridge crossing the Mekong River in Kratie province, a road from Staung district of Kampong Thom province to Kratie province, and a bridge across the Tonle Sap River and a road connecting Kampong Chhnang province and Kampong Thom province.
Cambodia has also been studying the construction of a road linking Battambang and Siem Reap provinces, he added, stressing that he had also allowed the study of a road from Lovea Em district of Kandal province to the newly-inaugurated NR11.
COVID-19 pandemic has cost Cambodia a lot of national budget, if there was no COVID-19, the Lovea Em-NR11 road construction project would start immediately, he said.
Samdech Techo Prime Minister took the opportunity to thank China for always supporting the infrastructure development in Cambodia. So far, he indicated, China has assisted the construction of more than 3,000 kilometres of road and many bridges in the Kingdom.

Source: Agency Kampuchea Press

Fiji Now Offering Quarantine-Free Travel to Visitors from Cambodia

Fiji started offering quarantine-free travel to vaccinated visitors from Cambodia last week, according to the Pacific island nation’s Ministry of Commerce, Trade, Tourism and Transport.
The ministry says Cambodia is among several dozen countries designated as Fiji Travel Partners whose entry requirements are easier than those for non-partner countries.
Apart from Cambodia, the ministry says only three other Asian countries have the partner designation — Japan, South Korea and Singapore.
Fiji opened to vaccinated visitors on Dec. 1.
“In this new world we live in, it’s nice to know there’s still a place where you can find true happiness,” the ministry says.
Located between Australia and Hawaii, the Melanesian archipelago has traditionally been a popular destination for tourists from Australia, New Zealand and the United States.
A Phnom Penh travel agent said Fiji Airways currently has weekly flights to Singapore, which is due to start offering quarantine-free travel from six more countries including Cambodia next week. The other five are Fiji, Sri Lanka, the Maldives, Thailand and Turkey.
Fiji is the largest Melanesian nation after Papua New Guinea and its capital Suva serves as a regional centre for the South Pacific. Melanesia also includes the Solomon Islands, Vanuatu and the French colony of New Caledonia.

Source: Agency Kampuchea Press

“Theatre of the absurd”: UN human rights expert denounces Suu Kyi sentence

GENEVA (6 December 2021) – A UN human rights expert derided the sentencing of Aung San Suu Kyi and Win Myint to four years in jail by a military-controlled court in Myanmar as the “theatre of the absurd”, saying the hearing underscored the complete lack of rule of law in the country.
“State Counselor Aung San Suu Kyi and President Win Myint are hostages, not criminals,” said UN Special Rapporteur on the situation of human rights in Myanmar, Tom Andrews. “This proceeding should not be confused with an actual trial – it is theatre of the absurd and a gross violation of human rights.
“Aung San Suu Kyi, and thousands of others, are being arbitrarily detained in a system of injustice, guilty of only exercising their fundamental rights.”
Aung San Suu Kyi and President Win Myint were jailed on Monday on charges of incitement and breaching coronavirus restrictions.
“Today’s sentencing demonstrates why the international community must take stronger action to support the people of Myanmar by denying the junta the revenue and weapons that they need to continue their illegitimate grip on the people of Myanmar.
“I call upon Member States to significantly increase pressure on the junta as a result of this outrageous action.”
The junta’s arrest and sentencing of Aung San Suu Kyi and thousands of others highlights the relentless assault on the people of Myanmar’s right to exercise their civil and political rights, Andrews said.
One of the charges Aung San Suu Kyi and Win Myint were sentenced under—Section 505(b) of the Penal Code—criminalizes speech that may cause “fear or alarm to the public” or that leads others to upset “public tranquility.” Relying on this provision, as well as draconian and illegitimate amendments to other existing laws and regulations, the junta has systematically violated the people of Myanmar’s right to freedom of expression, freedom of peaceful assembly and association, and access to information.
Reports indicate that after the verdict of this sham trial was released, peaceful protesters were executed on the streets of Yangon by junta forces, Andrews said. A military vehicle ran directly into them while exercising their basic right of free speech.
“What more do we need to see from this illegal military junta before the international community takes decisive, principled action?” Andrews asked.

Source: UN Human Rights Council

Cambodia’s Hun Sen softens statements backing succession by son

Cambodian prime minister Hun Sen on Monday walked back recent statements vowing exclusive support for the candidacy of his son to someday replace him in office, saying the contest is still open, Cambodian sources said.
Analysts said that Hun Sen, who has held power in Cambodia for more than 35 years, may have softened his stance over fear of provoking a damaging rift within his ruling Cambodian People’s Party (CPP).
Speaking on Monday at the opening of a new national road in southeastern Cambodia’s Prey Veng province, Hun Sen said that he himself will run for reelection in any case in 2023.
Hun Sen’s son Hun Manet, 44, will not be eligible to run for the country’s top political job until 2028, he said, adding that the CPP at that time should have at least four candidates contending for the post.
“I can say that Hun Manet will be one of the candidates. This does not mean that he’ll be the only candidate,” Hun Sen said.
He also urged the son of the current Defense Minister Tea Banh, the son of Interior Minister Sar Kheng, and the son of the National Assembly’s first vice-president Cheam Yeap to compete for the position.
“Their opportunity to run will not come before 2028, though, and will probably be sometime between 2028, 2029, and 2030. They will have to wait,” he said.
Following Hun Sen’s statement, Sar Kheng’s son Sar Sokha, who now serves as secretary of state for Cambodia’s Ministry of Education, quickly issued his own endorsement for Hun Manet — who already commands Cambodia’s army as a three-star general — to be Cambodia’s next prime minister.
Cambodian political analyst Kim Sok, now living in exile in Finland, said that Hun Sen’s retreat from endorsing his son at a public event last week to someday succeed him shows concern over unrest within the CPP.
“It was normal, when Hun Sen raised this matter publicly before, for Sar Kheng, who was sitting behind him in the ceremony, not to express any public opposition,” he said.
“But Hun Sen now has to release some of this tension so that the public will not feel that Cambodia is following the example of North Korea by establishing a family dynasty.”
Hun Sen’s own position as prime minister is not fully legitimate, Kim Sok said, adding that by elevating Hun Manet to high office, Hun Sen may only be subjecting his son to unwelcome international scrutiny.
Based on party ranking order, Sar Kheng should succeed Hun Sen as prime minister in any case, said U.S.-based Cambodian political analyst So Naro.
“Like it or not, it should be Sar Kheng who receives the transfer of power,” he said.
Sok Ey San, spokesman for the CPP, denied the existence of any tension within the ruling party, saying Cambodian opposition groups have pointed to what he called imagined rifts within the CPP for more than 40 years.
“There is no division at all,” he said.
Cambodia’s Supreme Court dissolved the country’s main opposition party, the Cambodia National Rescue Party, in November 2017 over an alleged plot backed by the United States to topple the government.
The move to ban the CNRP was part of a wider crackdown by Hun Sen on political opponents, NGOs, and the independent media that paved the way for the Cambodian People’s Party to win all 125 seats in the country’s July 2018 general election.

Copyright © 1998-2016, RFA. Used with the permission of Radio Free Asia, 2025 M St. NW, Suite 300, Washington DC 20036Radio Free Europe–Copyright (c) 2015. RFE/RL, Inc. Reprinted with the permission of Radio Free Europe/Radio Liberty, 1201 Connecticut Ave NW, Ste 400, Washington DC 20036.

Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12

First and only neutralizing antibody therapy for this age group

SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (the “FDA”) has expanded the emergency use authorization (“EUA”) for etesevimab (JS016/LY-CoV016) and bamlanivimab (LY-CoV555) administered together (the “Therapy”) to include certain high-risk pediatric patients from birth to under 12 years old for the treatment of mild to moderate COVID-19 as well as post-exposure prophylaxis, according to Eli Lilly and Company (“Lilly”), the company’s global partner. The Therapy has been the first and only authorized neutralizing antibody therapy for emergency use in COVID-19 individuals under the age of 12 and offers treatment and prevention options to high-risk individuals of any age.

In February 2021, the Therapy was granted EUA for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization by the FDA. In September 2021, the Therapy was granted EUA for post-exposure prophylaxis in high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination and have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in an institutional setting, including a nursing home or prison.

The expanded EUA is based on safety and efficacy data of pediatric and infant patients in BLAZE-1 (NCT04427501), a phase II/III clinical trial studying the Therapy for the treatment of mild to moderate COVID-19 and who are at high risk for severe disease progression. The median time to complete symptom resolution as recorded in a trial-specific daily symptom diary was 7 days for subjects treated with etesevimab (1,400 mg) and bamlanivimab (700 mg) and 5 days for subjects treated with weight-based dosing of etesevimab and bamlanivimab. No pediatric subject died or required hospitalization due to COVID-19.

Pseudovirus and authentic virus studies demonstrate that the Therapy retains neutralization activity against the Delta (B.1.617.2/AY.3) variant, the currently predominant variant of concern worldwide.

According to the statistics from Lilly, over 700,000 patients have been treated with the Therapy or bamlanivimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths during the worst of the pandemic.

About Etesevimab (JS016/LY-CoV016)
Etesevimab is a recombinant fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from the Company after it was jointly developed by the Company and the Institute of Microbiology, Chinese Academy of Science. The Company leads development in Greater China (including mainland China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region and the Taiwan region), while Lilly leads development in the rest of the world. The Therapy has obtained EUA in more than 15 countries and regions worldwide. The Company has completed a Phase Ib/II international multi-center clinical study (NCT04780321) of etesevimab for patients with mild to moderate COVID-19. Results from a Phase 2/3 study sponsored by Lilly in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) were published in the New England Journal of Medicine.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 45 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in 15 countries and regions worldwide. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800